Ambrx Gains $10M

La Jolla-based Ambrx, which is developing protein and antibody drugs, said in a regulatory filing today that it has raised $10M. No details of the funding round have been disclosed. Ambrx has previously raised capital from 5AM Ventures, Maverick, Tavistock Life Sciences, CMEA Capital, Versant Ventures, Twilight Venture Partners, Aravis, Alexandria Equities, and Apposite. More information »